ArticleFrontiers in endocrinology2026
Identification of key genes and metabolites in thyroid eye disease through integrated transcriptomic and metabolomic analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid eye disease (TED) markedly compromises ocular function and quality of life, imposing significant healthcare and economic burdens. Present therapeutic strategies, which mainly include glucocorticoids, teprotumumab, immunosuppressive drugs, and surgical treatments, exhibit limited effectiveness and are associated with high rates of relapse. Consequently, unraveling the molecular mechanisms of TED and discovering new diagnostic and therapeutic targets hold immense clinical importance. Methods: In this study, we performed an in-depth analysis of the transcriptomic and metabolomic landscapes of orbital adipose tissue in individuals with TED, aiming to fill the gap in comprehensive molecular characterizations and metabolic perturbations in this disease. By adopting a multi-omics integration strategy, we leveraged transcriptome sequencing, broad-spectrum metabolomics, weighted gene co-expression network analysis (WGCNA), machine learning, immune cell infiltration profiling, molecular docking, QPCR, and immunohistochemistry for biomarker identification. These techniques were systematically employed to pinpoint key genes and metabolites associated with TED, leading to the development of an accurate disease prediction model. Results: Remarkably, our analysis of the PRJNA1314138 dataset revealed 4, 250 differentially expressed genes (DEGs), with BPIFA1 and SERPINB3 identified as crucial genes through machine learning algorithms. These genes demonstrated outstanding predictive performance in both internal [Area under the curve (AUC)=0.953] and external dataset validations (AUC = 0.717). Furthermore, metabolomic profiling detected 2, 158 metabolites, pinpointing three key metabolites: gluconic acid, colneleic acid, and isoleucine-methionine. The integration of transcriptomic and metabolomic data underscored the significant enrichment of the tyrosine metabolism pathway, establishing functional links between the identified genes and metabolites. Conclusion: These insights offer novel perspectives on the molecular foundations of TED and propose that BPIFA1 and SERPINB3 could serve as promising biomarkers, while gluconic acid, colneleic acid and isoleucine-methionine may hold potential as metabolic indicators. Our research provides a solid framework for comprehending the pathophysiology of TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.